Vabysmo (Faricimab)

About Roche

Roche is a global healthcare leader with a unique dual-pillar strategy combining its Pharmaceuticals and Diagnostics divisions to address the full patient journey. Under CEO Thomas Schinecker, the company focuses on preventing disease through early identification, halting progression via targeted therapies, and restoring health with curative medicines. With a market cap of ~$256B, it leverages its integrated platform to drive innovation in oncology, neurology, immunology, and infectious diseases, while pursuing sustainable, long-term growth.

About XOMA

XOMA Royalty Corporation has strategically transformed from a traditional drug discovery company into a specialized biotech royalty aggregator, acquiring future economic rights to milestone and royalty payments from partnered therapeutic assets. Its mission is to provide non-dilutive, non-recourse capital to biotech innovators, building a diversified portfolio of over 120 assets to mitigate binary risk while participating in the upside of drug development. Key achievements include securing a $140 million financing facility backed by its VABYSMO® royalties and building a portfolio with its first FDA-approved asset, VABYSMO, now generating revenue. The strategy focuses on leveraging scientific diligence to acquire rights to pre-commercial assets with blockbuster potential, operated by well-capitalized partners, under a capital-efficient corporate structure.

Therapeutic Areas